Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026
· Financial Post
VANCOUVER, British Columbia, April 21, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced results from the dose-escalation part of the Phase 1 study for ZW191, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), at the 2026 American Association for Cancer Research (AACR) Annual Meeting. Read More
Visit somethingsdifferent.biz for more information.